Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -190,886 | -257,590 | -327,265 | -340,414 | -182,051 |
| Depreciation Amortization | 8,138 | 5,291 | 7,390 | 17,186 | 17,409 |
| Accounts payable and accrued liabilities | -1,231 | -503 | -7,502 | 4,868 | -767 |
| Other Working Capital | -10,877 | -24,799 | -21,307 | 3,897 | -31,949 |
| Other Operating Activity | 45,610 | 77,301 | 110,951 | 93,944 | 12,546 |
| Operating Cash Flow | $-149,246 | $-200,300 | $-237,733 | $-220,519 | $-184,812 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -386 | -694 | -1,516 | -5,191 | -21,446 |
| Purchase Of Investment | -138,257 | -361,475 | -438,629 | -248,109 | -543,293 |
| Sale Of Investment | 234,202 | 437,857 | 603,434 | 359,459 | 728,394 |
| Investing Cash Flow | $95,559 | $75,688 | $163,289 | $106,159 | $163,655 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 23,249 | 114,395 | 95,695 | 2,950 | 11,963 |
| Other Financing Activity | 6,908 | 2,280 | 0 | 0 | 0 |
| Financing Cash Flow | $30,157 | $116,675 | $95,695 | $2,950 | $11,963 |
| Beginning Cash Position | 85,510 | 93,447 | 72,196 | 183,606 | 192,800 |
| End Cash Position | 61,980 | 85,510 | 93,447 | 72,196 | 183,606 |
| Net Cash Flow | $-23,530 | $-7,937 | $21,251 | $-111,410 | $-9,194 |
| Free Cash Flow | |||||
| Operating Cash Flow | -149,246 | -200,300 | -237,733 | -220,519 | -184,812 |
| Capital Expenditure | -386 | -694 | -1,516 | -5,191 | -21,446 |
| Free Cash Flow | -149,632 | -200,994 | -239,249 | -225,710 | -206,258 |